BioSante's CML vaccine gains orphan-drug status from FDA

06/7/2010 | International Business Times · Reuters

BioSante Pharmaceuticals said its experimental vaccine GVAX CML was granted orphan-drug designation by the FDA for treating patients with chronic myeloid leukemia. The drugmaker previously obtained orphan status for two other GVAX vaccines to treat pancreatic cancer and acute myeloid leukemia.

View Full Article in:

International Business Times · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC